Puma Biotechnology, Inc. (PBYI)

US — Healthcare Sector
Peers: RARE  CRNX  ARVN  RVMD  KURA  TSVT  ICPT  IOVA  SRPT  MDGL  VKTX  HEPA  PTCT  HRTX  CHRS  LRMR  MGNX 

Automate Your Wheel Strategy on PBYI

With Tiblio's Option Bot, you can configure your own wheel strategy including PBYI - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol PBYI
  • Rev/Share 4.6921
  • Book/Share 1.958
  • PB 1.8642
  • Debt/Equity 0.5259
  • CurrentRatio 1.529
  • ROIC 0.2805

 

  • MktCap 181179065.0
  • FreeCF/Share 0.6284
  • PFCF 5.8132
  • PE 4.7554
  • Debt/Assets 0.2603
  • DivYield 0
  • ROE 0.493

 

  • Rating A-
  • Score 4
  • Recommendation Buy
  • P/E Score 2
  • DCF Score 3
  • P/B Score 3
  • D/E Score 2

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Why Fast-paced Mover Puma Biotech (PBYI) Is a Great Choice for Value Investors
PBYI
Published: May 28, 2025 by: Zacks Investment Research
Sentiment: Positive

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Puma Biotech (PBYI) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Read More
image for news Why Fast-paced Mover Puma Biotech (PBYI) Is a Great Choice for Value Investors
Despite Fast-paced Momentum, Puma Biotech (PBYI) Is Still a Bargain Stock
PBYI
Published: May 12, 2025 by: Zacks Investment Research
Sentiment: Positive

Puma Biotech (PBYI) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

Read More
image for news Despite Fast-paced Momentum, Puma Biotech (PBYI) Is Still a Bargain Stock
Is Puma Biotechnology (PBYI) Stock Undervalued Right Now?
PBYI
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Positive

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Read More
image for news Is Puma Biotechnology (PBYI) Stock Undervalued Right Now?
PBYI Stock Rises as Q1 Earnings and Sales Beat Estimates
PBYI
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Positive

Puma Biotechnology PBYI reported first-quarter 2025 adjusted earnings of 10 cents per share, which beat the Zacks Consensus Estimate of 2 cents. In the year-ago quarter, the company had incurred a loss of 5 cents per share.

Read More
image for news PBYI Stock Rises as Q1 Earnings and Sales Beat Estimates
Puma Biotechnology, Inc. (PBYI) Q1 2025 Earnings Call Transcript
PBYI
Published: May 09, 2025 by: Seeking Alpha
Sentiment: Neutral

Puma Biotechnology, Inc. (NASDAQ:PBYI ) Q1 2025 Results Conference Call May 8, 2025 4:30 PM ET Company Participants Mariann Ohanesian - Senior Director Investor Relations Alan Auerbach - President & Chief Executive Officer Jeff Ludwig - Chief Commercial Officer Heather Blaber - VP of Marketing Roger Storms - VP of Sales Maximo Nougues - Chief Financial Officer Conference Call Participants Divya Rao - Cowen Operator Good afternoon. My name is Sherry, and I will be your conference call operator today.

Read More
image for news Puma Biotechnology, Inc. (PBYI) Q1 2025 Earnings Call Transcript
Puma Biotech (PBYI) Upgraded to Strong Buy: Here's What You Should Know
PBYI
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Positive

Puma Biotech (PBYI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Read More
image for news Puma Biotech (PBYI) Upgraded to Strong Buy: Here's What You Should Know
Er-Kim Announces Exclusive Distribution Agreement with Puma Biotechnology to Commercialize NERLYNX® (neratinib) for Breast Cancer Patients
PBYI
Published: April 30, 2025 by: GlobeNewsWire
Sentiment: Neutral

ATHENS, Greece and LOS ANGELES, April 30, 2025 (GLOBE NEWSWIRE) -- Er-Kim, an international pharmaceutical company specializing in the commercialization of novel therapies in the EMEA region, today announced that it has signed an agreement with Puma Biotechnology, Inc. (NASDAQ: PBYI) to commercialize NERLYNX® (neratinib) in select countries in Eastern Europe and Central Asia. NERLYNX is designed to block human epidermal growth factor receptor 2 (HER2) in order to treat and limit breast cancer metastasis.

Read More
image for news Er-Kim Announces Exclusive Distribution Agreement with Puma Biotechnology to Commercialize NERLYNX® (neratinib) for Breast Cancer Patients
Should Value Investors Buy Puma Biotechnology (PBYI) Stock?
PBYI
Published: April 23, 2025 by: Zacks Investment Research
Sentiment: Positive

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Read More
image for news Should Value Investors Buy Puma Biotechnology (PBYI) Stock?
Are Investors Undervaluing Puma Biotechnology (PBYI) Right Now?
PBYI
Published: March 03, 2025 by: Zacks Investment Research
Sentiment: Positive

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Read More
image for news Are Investors Undervaluing Puma Biotechnology (PBYI) Right Now?
Puma Biotechnology, Inc. (PBYI) Q4 2024 Earnings Call Transcript
PBYI
Published: February 27, 2025 by: Seeking Alpha
Sentiment: Neutral

Puma Biotechnology, Inc. (NASDAQ:PBYI ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Mariann Ohanesian – Senior Director-Investor Relations Alan Auerbach – President and Chief Executive Officer Jeff Ludwig – Chief Commercial Officer Maximo Nougues – Chief Financial Officer Conference Call Participants Ed White – H.C. Wainwright Marc Frahm – TD Cowen Operator Good afternoon.

Read More
image for news Puma Biotechnology, Inc. (PBYI) Q4 2024 Earnings Call Transcript

About Puma Biotechnology, Inc. (PBYI)

  • IPO Date 2012-04-24
  • Website https://www.pumabiotechnology.com
  • Industry Biotechnology
  • CEO Mr. Alan H. Auerbach
  • Employees 172

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.